Compare IDCC & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDCC | ABVX |
|---|---|---|
| Founded | 1972 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | |
| Sector | Miscellaneous | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 7.7B |
| IPO Year | 2007 | 2022 |
| Metric | IDCC | ABVX |
|---|---|---|
| Price | $289.99 | $87.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $462.67 | $163.58 |
| AVG Volume (30 Days) | 198.4K | ★ 822.0K |
| Earning Date | 10-29-2026 | 09-21-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.86 | N/A |
| Revenue | ★ $307,404,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,695.54 |
| P/E Ratio | $37.45 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $249.14 | $69.81 |
| 52 Week High | $387.30 | $148.83 |
| Indicator | IDCC | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 38.72 | 46.03 |
| Support Level | $272.01 | $83.83 |
| Resistance Level | $296.49 | $97.99 |
| Average True Range (ATR) | 12.81 | 3.62 |
| MACD | -1.97 | 0.83 |
| Stochastic Oscillator | 12.23 | 46.81 |
InterDigital Inc is a research and development company focused on wireless, Video, Artificial Intelligence, and related Technologies. It designs and develops technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. The majority of revenue is generated from fixed-fee patent license agreements, with a smaller portion coming from variable royalty agreements. Geographically, it operates in the United States, China, South Korea, Japan, Taiwan, and Europe, with the majority is from China.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.